Engineered immune cells take on lupus and other autoimmune diseases
NCT ID NCT07212322
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new treatment called CD19 UCAR-T cells for people with autoimmune diseases like lupus, vasculitis, and Sjögren's syndrome. The therapy uses modified immune cells to target and calm the overactive immune system. The main goals are to check safety and see if it helps control the disease. The study plans to enroll 24 adults aged 18 to 65.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood platelet trends may reveal hidden risk in autoimmune disease
- Can a new biologic tame lupus flares?
- Could a single injection tame lupus and Sjögren's?
- Can a single infusion tame tough lupus?
- Immune clues in the blood may foretell heart trouble
- Can a simple blood test tell two forms of a clotting disorder apart?